D. E. Shaw & Co., Inc. Rain Therapeutics Inc. Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$11.91 - $17.0 $189,642 - $270,691	-15,923 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.21 - $20.91 $155,864 - $246,717	-11,799 Reduced 42.56%	15,923 $238,000
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $418,047 - $562,756	27,722 New	27,722 $431,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.